The 2026 ISPE Facilities of the Future Conference will take place from 2–3 February 2026 in
San Diego, California, United States, and virtually.
NORTH BETHESDA, Md., Dec. 4, 2025 /PRNewswire/ — The International Society for Pharmaceutical Engineering (ISPE) has announced its keynote speakers for the 2026 ISPE Facilities of the Future Conference, set for Monday, 2 February, through Tuesday, 3 February, in San Diego, California, United States, and virtually.
“The 2026 ISPE Facility of the Future Conference enables us to build our future together, as an industry. Experts and practitioners from around the world come together to share ideas, learn from real-world implementations, and benchmark with peers to improve processes and innovate,” said Lindsey Daniel, PE, Global Head of Operational Excellence, Biologics Network, Takeda.
This year’s conference will feature four tracks. Each track consists of carefully curated educational sessions, with data-driven insights, case studies, and real-world examples:
ISPE has announced its keynote speakers for the event:
The event will also feature:
Learn more and register for the 2026 ISPE Facilities of the Future Conference today.
About ISPE
The International Society for Pharmaceutical Engineering (ISPE) is a global nonprofit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 25,000+ members of ISPE provide solutions to complex pharmaceutical industry challenges through innovation, member and workforce development, and technical, regulatory, and compliance collaborations in more than 120 countries worldwide. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland, USA, and its operations center in Tampa, Florida, USA. For more information, visit ISPE.org.
SOURCE ISPE
TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription…
Concludes Distribution Agreement with Gore® for VIABIL® in the United States and Canada, Effective January…
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern…
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard…
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the…